摘要
人表皮生长因子受体2(HER2)基因扩增或其编码的蛋白过表达与多种肿瘤密切相关,其在结直肠癌(CRC)患者中的发生率约为3%,在携带野生型RAS或BRAF基因的肿瘤患者中发生率约为5%。目前,HER2作为转移性结直肠癌(mCRC)患者预后生物标志物的作用仍不明确,但HER2基因扩增状态对mCRC患者的靶向治疗选择具有较大影响,抗HER2靶向治疗也为HER2基因扩增或其编码的蛋白过表达型mCRC患者提供了新的选择。本文通过概述HER2基因扩增状态对一线靶向治疗的影响、下游基因状态对HER2基因扩增状态检测和治疗的作用以及抗HER2靶向治疗研究进展,以期为HER2基因扩增或其编码蛋白的过表达型mCRC的基因检测和靶向治疗提供参考。
The amplification/overexpression of human epidermal growth factor receptor 2(HER2)is related with many cancer types,and it occurs in about 3% of patients with colorectal cancer(CRC)and in about 5% of patients with tumors carrying wild-type RAS or BRAF genes.At present,the role of HER2 as a prognostic biomarker in patients with metastatic colorectal cancer(mCRC)is still unclear,but the amplification status of HER2 has a great influence on the choice of targeted therapy for mCRC patients.Anti-HER2 targeted therapy also provides a new option for mCRC patients with HER2 amplification/overexpression.In this paper,we summarize the influence of HER2 amplification status on first-line targeted therapy,the role of downstream gene status on detection and treatment of HER2 amplification status,and the research progress of anti-HER2 targeted therapy,in order to provide reference for gene detection and targeted therapy of mCRC with HER2 amplification/overexpression.
作者
唐平秀
杜琼
王萌萌
郭子寒
叶璇
单瀚
TANG Ping-xiu;DU Qiong;WANG Meng-meng;GUO Zi-han;YE Xuan;SHAN Han(Department of Pharmacy,Hehai University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College Hehai University,Shanghai 200032,China;Department of Pharmacy,Suining Central Hospital,Suining 629000,China)
出处
《中国合理用药探索》
2022年第9期29-34,共6页
Chinese Journal of Rational Drug Use
